Key facts
- Notable investors include Zhongguancun Development Venture Capital Fund, China Growth Capital, Co-Win Ventures, Tianjin Venture Capital, DeepStream Global Management — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for InnoVec
- ·The full record, as it builds
Funding rounds
No funding rounds for InnoVec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InnoVec
Developer of gene therapy delivery vehicles and drugs intended to solve gene delivery problems in all tissues and organs of the human body. The company's technology platform includes adeno-associated viruses (AAV), gene editing and other related production processes, thereby providing medical industry users with innovative medical solutions.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2020
- Website
- innovecbio.com/
- Ownership
- Privately Held (backing)
InnoVec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InnoVec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InnoVec in its N-PORT filings yet. We sweep new filings monthly.